While the proposal highlights the government's struggle to ramp up production of homegrown biofuels that are cleaner-burning than gasoline, but is unlikely to mean much for consumers at the pump.
The change would require almost 3 billion gallons less ethanol and other biofuels to be blended into gasoline in 2014 than the law requires.
The 2007 law tried to address global warming by requiring oil companies to blend billions of gallons of biofuels into their gasoline each year. But politicians who wrote the law didn't anticipate fuel economy to improve as much as it has in recent years, which reduced demand for gasoline.
5 Best Construction Material Stocks To Invest In Right Now: Federal-Mogul Corporation(FDML)
Federal-Mogul Corporation supplies powertrain and safety technologies worldwide. The company?s Powertrain Energy segment offers powertrain components, such as engine pistons, piston rings, piston pins, cylinder liners, camshafts, valve seats and guides, and ignition products under the Federal-Mogul, AE, Champion, Goetze, Nural, and Daros brand names. Its Powertrain Sealing and Bearings segment provides dynamic seals, bonded piston seals, combustion and exhaust gaskets, static gaskets and seals, rigid heat shields, engine bearings, industrial bearings, bushings and washers, sintered engine and transmission components, and metallic filters, as well as polymer bearings primarily under the Federal-Mogul, Deva, Fel-Pro, FP Diesel, Glyco, Metafram, Metagliss, National, Payen, and Poral brand names. The company?s Vehicle Safety and Protection segment offers brake disc pads, brake linings, brake blocks, element resistant systems protection sleeving products, flexible heat shield s, brake system components, chassis products, windshield wipers, fuel pumps, and lighting products under the Federal-Mogul, Abex, Anco, Bentley-Harris, Beral, Champion, Ferodo, Moog, ThermoQuiet, and Wagner brands. Its Global Aftermarket segment provides aftermarket products to distributors, retail parts stores, and mass merchants who distribute these products to professional service providers and do-it-yourself consumers under the Abex, AE, ANCO, Beral, Carter, Champion, Fel-Pro, Ferodo, FP Diesel, Glyco, Goetze, MOOG, National, Necto, Nural, Payen, Sealed Power, ThermoQuiet, and Wagner brand names. The company serves original equipment manufacturers of automotive, as well as light, medium and heavy-duty commercial vehicles; and agricultural, marine, rail, aerospace, off-road, and industrial applications, as well as the aftermarket sector. The company was founded in 1899 and is headquartered in Southfield, Michigan. Federal-Mogul Corporation is a subsidiary of Icahn Enterpr ises L.P.
Advisors' Opinion:- [By Lauren Pollock]
Honeywell International Inc.(HON) agreed to sell its friction-materials business unit to Federal-Mogul Corp.'s(FDML) (FDML) European business for roughly $155 million. The deal, expected to close in the second half of this year, includes two plants in China and Romania.
- [By Sean Williams]
What: Shares of Federal-Mogul (NASDAQ: FDML ) , an auto parts and vehicles components supplier, soared 26% after the company handily topped Wall Street's EPS expectations in the second quarter.
- [By Rich Smith]
Southfield, Mich.-based Federal-Mogul (NASDAQ: FDML ) already has one chief executive officer, but as the Russians like to say, "Too much is better than not enough" -- so today, the company hired another.
- [By Jeremy Bowman]
What: Shares of Federal-Mogul (NASDAQ: FDML ) were charging higher today, gaining as much as 13% after announcing a new line of components for its "industry-leading" MOOG line of steering and suspension parts.
Top 5 Up And Coming Stocks For 2014: San Miguel Brewery Hong Kong Ltd (MBR)
San Miguel Brewery Hong Kong Limited is a Hong Kong-based company engaged in the manufacture and distribution of bottled, canned and draught beers. The Company operates in two segments: The Hong Kong operation mainly represents the manufacture and distribution of own brewed beer products and distribution of imported beer products in Hong Kong and overseas, and the mainland China operation mainly represents the manufacture and distribution of own brewed beer products in the southern part of the People�� Republic of China and overseas. Its subsidiaries include Best Investments International Inc., Hongkong Brewery Limited, Ravelin Limited, San Miguel (Guangdong) Limited, Guangzhou San Miguel Brewery Company Limited, San Miguel Shunde Holdings Limited and San Miguel (Guangdong) Brewery Company Limited. Advisors' Opinion:- [By Geoffrey Seiler]
This was a solid quarter from Aetna, highlighted by much stronger-than-expected results from its Commercial and Medicaid segments. The rebound in the Medicaid medical benefits ratio (MBR) was particularly notable.
Top 5 Up And Coming Stocks For 2014: Koss Corporation(KOSS)
Koss Corporation, together with its subsidiary, Koss Classics Ltd., designs, manufactures, and sells stereo headphones and related accessories primarily in the United States and Europe. It offers a line of high-fidelity stereo headphones, speaker-phones, computer headsets, telecommunications headsets, active noise canceling stereo headphones, wireless stereo headphones, and compact disc recordings of American Symphony Orchestras under the Koss Classics label. The company sells its products through national retailers, international distributors, audio specialty stores, the Internet, direct mail catalogs, regional department store chains, discount department stores, military exchanges, and prisons under the Koss name. It also sells its products to distributors for resale to school systems, and directly to other manufacturers. The company was founded in 1953 and is based in Milwaukee, Wisconsin.
Advisors' Opinion:- [By John Udovich]
Yesterday after the market closed, small cap audio stock Skullcandy Inc (NASDAQ: SKUL) reported earnings and began rising in after hours trading, meaning its worth taking a closer look at the stock along with the performance of other audio stocks like mid cap Harman International Industries Inc (NYSE: HAR) and small caps Koss Corporation (NASDAQ: KOSS) and Parametric Sound Corp (NASDAQ: PAMT). I should mention that in�late 2012, Skullcandy had the dubious distinction of being the market�� most shorted stock (see: Long Live the Shorts or the Short Squeeze? SKUL, AM & UBNT) with short�interest of 86.47% and there would still be a lot of shorts out there who might start feeling the squeeze (Note: SKUL is at least no longer on the HighShortInterest.com list)
- [By Jason Rivera]
Koss Corporation (KOSS) was no different because after looking over its balance sheet and profitability numbers I found substantial NOLs, little debt and reasonable profitability levels which usually are good signs that the company may be a good investment if the company is undervalued. This however is not an article about a company that I will ever invest in due to it being a grossly overvalued, dying company, which has major management concerns.
Top 5 Up And Coming Stocks For 2014: Myriad Genetics Inc (MYGN)
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).
As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.
Molecular Diagnostic Tests
The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.
The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.
The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.
Companion Diagnostic Services and Other Revenue
! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.
The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.
Advisors' Opinion:- [By Jon C. Ogg]
Myriad Genetics Inc. (NASDAQ: MYGN) was downgraded to Market Underperform from Market Perform at JMP Securities. Keep in mind that shares are getting knocked down about 10% based on the Centers for Medicare and Medicaid Services lowering its reimbursement rate by almost half for its breast cancer testing.
- [By John Udovich]
On Monday, small cap molecular diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) suddenly sank 9.34% to $23.50 just before the market closed���meaning its probably a good idea to take a closer look at what happened yesterday plus compare the stock�� performance verses small cap peer Sequenom, Inc (NASDAQ: SQNM) and mid cap peer Hologic, Inc (NASDAQ: HOLX).�
No comments:
Post a Comment